Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR-17 Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Research and development
      • XR-18
      • XR-19
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • Key value drivers
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact

Press releases

All releases
  • Regulatory Releases
  • Press Releases
2017
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • All years
Regulatory
December 11, 2017

Oasmia Pharmaceutical receives marketing approval for Paclical® in Kazakhstan

Regulatory
December 1, 2017

Oasmia Pharmaceutical AB (publ) Interim report for the period May – October 2017

Regulatory
November 30, 2017

Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 28,000,000

Regulatory
October 4, 2017

Oasmia Pharmaceutical AB Announces Resignation of its Chief Financial Officer

Regulatory
October 2, 2017

Nexttobe Extends Loan to Oasmia Pharmaceutical

Regulatory
September 29, 2017

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory
September 25, 2017

Annual General Meeting of Oasmia Pharmaceutical AB (publ) held on 25 September 2017

Regulatory
September 21, 2017

Supplementary proposals of the Nomination Committee for the 2017 Annual General Meeting

Regulatory
September 11, 2017

Notification from Oasmia Pharmaceutical AB

Regulatory
September 1, 2017

Oasmia Pharmaceutical AB (publ)

Regulatory
August 31, 2017

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory
August 25, 2017

NOTICE OF ANNUAL GENERAL MEETING IN OASMIA PHARMACEUTICAL AB

Regulatory
August 8, 2017

Oasmia Pharmaceutical receives market approval for its Anti-Cancer Drug Doxophos® in Russia

Regulatory
July 31, 2017

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory
July 7, 2017

Oasmia Pharmaceutical AB (publ) announces result of the rights issue

Regulatory
July 7, 2017

The Oasmia Pharmaceutical Annual Report is now published

Regulatory
June 21, 2017

Issuance of warrants in Oasmia Pharmaceutical AB (publ)

Regulatory
June 19, 2017

Oasmia Pharmaceutical AB (publ) publishes prospectus by reason of the Rights Issue

Regulatory
June 14, 2017

Oasmia Pharmaceutical enters into new exclusive marketing and distribution agreement concerning Russia and other CIS markets

Regulatory
June 12, 2017

Oasmia Pharmaceutical AB (publ): The board of directors resolves upon a rights issue of approximately 163.9 MSEK

Regulatory
June 8, 2017

Oasmia Pharmaceutical AB (publ) replaces current convertible loan with new debt

Regulatory
June 8, 2017

Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2016 – April 30, 2017

Regulatory
June 2, 2017

Report from extra general meeting 2 June 2017

Regulatory
May 31, 2017

Number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory
May 29, 2017

Oasmia Pharmaceutical Issues Clarification Regarding Clinical Study OAS-12DOC-BIO

Regulatory
May 23, 2017

Oasmia Pharmaceutical Invites Shareholders to Capital Markets Day in Stockolm on June 15th

Regulatory
May 10, 2017

Oasmia convenes an extraordinary general meeting on 2 June, 2017

Regulatory
May 10, 2017

Oasmia Pharmaceutical to spin-off veterinary assets

Regulatory
May 1, 2017

Increased number of shares and votes in Oasmia Pharmaceutical AB (publ)

Regulatory
April 25, 2017

Conversion of SEK 42M convertible loan in Oasmia

Regulatory
April 18, 2017

Oasmia completes set-off private placements of new convertibles in the total amount of SEK 26 million with conversion rate of SEK 8.00

Regulatory
March 31, 2017

Oasmia successfully completes private placements of new convertibles in the total amount of SEK 42 million with conversion rate of SEK 5.95

Regulatory
March 30, 2017

Oasmia evaluates the possibility to carry out a private placement of new convertible instruments

Regulatory
March 21, 2017

Oasmia intends to issue convertible to replace current convertible loan

Regulatory
March 3, 2017

Interim report for the period May 2016 – January 2017

Regulatory
March 1, 2017

Clarification from the Board of Directors, Company Management and the Principal Shareholders of Oasmia Pharmaceutical AB (publ) Surrounding Anders Lönner’s Withdrawal from the Board of Directors

Regulatory
February 28, 2017

Oasmia Pharmaceuticals Chairman Anders Lönner Resigns

Regulatory
January 23, 2017

Oasmia Pharmaceutical Announces Strategic Move to Bolster Efforts for its Veterinary Division

Investor contact
[email protected]
+46 18-50 54 40

Subscribe to our news

  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancerpatients through a partnership with Elevar Therapeutics, Inc. Development programsinclude Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxelmicellar, in development for advanced prostate cancer. Vivesto has proprietary drugdelivery technology designed to improve solubility, efficacy and safety.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com